Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity

Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice

(2018) J. Morser et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects

(2017) J. Zhou et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Novel insights into the expression pattern of anaphylatoxin receptors in mice and men

(2017) Yves Laumonnier et al.   MOLECULAR IMMUNOLOGY

Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4

(2017) HongBin Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model ofEscherichia colisepsis

(2017) Ravi Shankar Keshari et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary HypertensionHighlights

(2016) Nobuhiro Yaoita et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Occupancy of human EPCR by protein C induces  -arrestin-2 biased PAR1 signaling by both APC and thrombin

(2016) R. V. Roy et al.   BLOOD

The versatile functions of complement C3-derived ligands

(2016) Anna Erdei et al.   IMMUNOLOGICAL REVIEWS

Structure-function relationships in thrombin-activatable fibrinolysis inhibitor

(2016) T. Plug et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules

(2016) Tom Plug et al.   THROMBOSIS RESEARCH

Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin

(2016) Jonathan H. Foley et al.   EBioMedicine

Is the Complement Activation Product C3a a Proinflammatory Molecule? Re-evaluating the Evidence and the Myth

(2015) Liam G. Coulthard et al.   JOURNAL OF IMMUNOLOGY

Inhibition of thrombin-activated fibrinolysis inhibitor decreases postoperative adhesion

(2015) Tae Han Kim et al.   JOURNAL OF SURGICAL RESEARCH

Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis

(2015) B. B. Mook-Kanamori et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model

(2015) Z. Shao et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Complement System Part II: Role in Immunity

(2015) Nicolas S. Merle et al.   Frontiers in Immunology

The Making of a Macromolecular Machine: Assembly of the Membrane Attack Complex

(2014) Doryen Bubeck   BIOCHEMISTRY

Thrombin-Activatable Fibrinolysis Inhibitor Protects against Acute Lung Injury by Inhibiting the Complement System

(2013) Masahiro Naito et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis

(2013) Xianzhen Hu et al.   IMMUNOBIOLOGY

Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms

(2013) D. Ricklin et al.   JOURNAL OF IMMUNOLOGY

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overview of Complement Activation and Regulation

(2013) Marina Noris et al.   SEMINARS IN NEPHROLOGY

TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation

(2013) Greg C. G. Hugenholtz et al.   THROMBOSIS AND HAEMOSTASIS

The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity

(2013) Joellen H. H. Lin et al.   THROMBOSIS AND HAEMOSTASIS

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)

(2013) John Rathbone et al.   BMJ Open

Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46

(2012) L. O. Mosnier et al.   BLOOD

The modular serine proteases of the complement cascade

(2012) Federico Forneris et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Regulation of the mouse gene encoding TAFI by TNFα: Role of NFκB binding site

(2012) Mathieu Garand et al.   CYTOKINE

The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency

(2012) E. VERCAUTEREN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Deletion of carboxypeptidase N delays onset of experimental cerebral malaria

(2012) M. M. DARLEY et al.   PARASITE IMMUNOLOGY

Effects of MASP-1 of the Complement System on Activation of Coagulation Factors and Plasma Clot Formation

(2012) Katharina Hess et al.   PLoS One

Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma

(2011) Atsushi Fujiwara et al.   LUNG

Procarboxypeptidase R Deficiency Causes Increased Lethality in Concanavalin A-Induced Hepatitis in Female Mice

(2010) Suzuka Asai et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis

(2010) I. Kourtzelis et al.   BLOOD

The complement system

(2010) J. Vidya Sarma et al.   CELL AND TISSUE RESEARCH

High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice

(2010) T. BEPPU et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor

(2010) L. QIN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

(2010) K. BUELENS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke

(2010) Peter Kraft et al.   PLoS One

The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing

(2010) Chantal J.N. Verkleij et al.   THROMBOSIS RESEARCH

EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats*

(2009) Yuko Muto et al.   CRITICAL CARE MEDICINE

Targeted Disruption of the Gene Encoding the Murine Small Subunit of Carboxypeptidase N (CPN1) Causes Susceptibility to C5a Anaphylatoxin-Mediated Shock

(2009) Stacey L. Mueller-Ortiz et al.   JOURNAL OF IMMUNOLOGY

Structures of potent selective peptide mimetics bound to carboxypeptidase B

(2008) Marc Adler et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation

(2008) P. F. Marx et al.   BLOOD

Thrombin-activable Fibrinolysis Inhibitor Zymogen Does Not Play a Significant Role in the Attenuation of Fibrinolysis

(2008) Jonathan H. Foley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (Activated Thrombin-activable Fibrinolysis Inhibitor), and Platelets

(2008) Xiao-Yan Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity

(2008) J. B. WALKER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency

(2008) Nelson E. Bruno et al.   THROMBOSIS AND HAEMOSTASIS

Major carboxypeptidase N deficiency

(2007) Johan L. Willemse et al.   CLINICA CHIMICA ACTA